Marc Beer, the founder of Renovia Inc., has opened the door to creating several products for pelvic floor disorders after raising 42 million dollars. Renovia is a company that develops devices that help treat a number of different pelvic floor disorders. All the funding that has been acquired during funding is going towards a line of new products for women’s health.
The diagnostic therapy he is developing can treat disorders such as urinary incontinence. This is is something that Renovia’s first product, Leva, can treat.
Healthcare investment firms, such as The Longwood Fund, is an early investor in Renovia’s research and products. The funding that is acquired is used to help the development and scientific testing of products that will help diagnosis pelvic floor disorders. Within this development, there is also a creation of a new generation of the Leva device underway.
Marc Beer is the founding CEO of ViaCell, a company that focuses on collecting, preserving, and developing umbilical cord stem cells. After seven years of rapid growth, ViaCell went public in 2005 and was eventually bought by PerkinElmer.
Before ViaCell, Marc was holding a variety of different positions in a company called Genzyme. In this position. While he was holding a position as CEO of ViaCell, Marc was also holding a position as a member within Erytech Pharma. Erytech Pharma is a publicly traded biopharmaceutical company.
Prior to his position at Genzyme, Marc held a number of different positions that centered around sales and marketing at Abbott Laboratories. He was responsible for sales and marketing for the pharmaceutical and diagnostic divisions within the company. During this time, he was also serving as a member of the Mass Life Science Board of Commonwealth of Massachusetts and Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board.
The other founding positions he was a part of included being a Chairman of Good Start Genetics, which was eventually acquired by InVitae, and being a chairman and member of the audit committee of Minerva Neurosciences Inc.
Marc Beer has brought over two decades of the development and global commercialization within the branches of biotech, pharmaceuticals, and diagnostic research. Learn more: https://people.equilar.com/bio/marc-beer-aegerion-pharmaceuticals-/salary/78453